Revance Therapeutics (RVNC) Tops Q3 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.60), $0.09 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $75 thousand, versus $158 thousand reported last year.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Texas Instruments (TXN) Reiterated at Neutral by Cantor Fitzgerald on Upside to Earnings Power
• Chilean Cobalt completes Phase 2 at NeoRe project, gets $1.5M investment
• Goldman Sachs hosts investor trip to Athens with Greek banks